흑색종 임상시험 결과
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and Aft
-
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has
-
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe
-
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage
-
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M
-
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizuma
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B
-
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
-
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
-
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
-
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Mel
-
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
-
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
-
Family Lifestyles, Actions, and Risk Education Intervention: Version 2
질환별 임상
폐암비소세포폐암유방암대장암위암간암췌장암전립선암난소암흑색종백혈병림프종다발성 골수종교모세포종제2형 당뇨병비만고혈압심부전심방세동뇌졸중만성 콩팥병비알코올 지방간염알츠하이머병파킨슨병다발성 경화증우울증뇌전증루게릭병류마티스 관절염건선아토피 피부염크론병궤양성 대장염루푸스천식만성폐쇄성폐질환